c-Met/HGFR
Gli inibitori di c-Met/HGFR mirano al Recettore del Fattore di Crescita degli Epatociti (c-Met), una tirosina chinasi coinvolta in processi cellulari come crescita, motilità e morfogenesi. La segnalazione di c-Met è implicata nella progressione del cancro, nella metastasi e nella resistenza alle terapie. L'inibizione di c-Met può interrompere la crescita e la diffusione del tumore, rendendo questi inibitori preziosi nella ricerca sul cancro. Presso CymitQuimica, offriamo inibitori di c-Met/HGFR per supportare la tua ricerca in oncologia, metastasi e terapie oncologiche mirate.
Trovati 128 prodotti di "c-Met/HGFR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Formula:C16H13N7OPeso molecolare:319.11816PROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Formula:C45H41FN10O5Colore e forma:SolidPeso molecolare:820.87Telisotuzumab
CAS:<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Purezza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Colore e forma:LiquidPeso molecolare:145.50 kDac-Met-IN-19
<p>c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,</p>Formula:C34H37Cl2FN4O7SPurezza:98%Colore e forma:SolidPeso molecolare:735.65Norleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Formula:C41H58N8O7Purezza:98%Colore e forma:SolidPeso molecolare:774.95BMS-777607
CAS:<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Formula:C25H19ClF2N4O4Purezza:98.16% - 98.56%Colore e forma:SolidPeso molecolare:512.89PF-04217903 methanesulfonate
CAS:<p>PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formula:C20H20N8O4SPurezza:98%Colore e forma:SolidPeso molecolare:468.49SYN1143
CAS:<p>SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.</p>Formula:C31H29FN4O5Purezza:99.69%Colore e forma:SolidPeso molecolare:556.58Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Formula:C30H24Cl2F2N6O3Colore e forma:SolidPeso molecolare:625.45NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Formula:C20H16N6Purezza:97.24% - >99.99%Colore e forma:SolidPeso molecolare:340.38Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C38H37FN4O8SPurezza:99.93%Colore e forma:SolidPeso molecolare:728.79Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C31H29FN4O5Purezza:99.95% - 99.98%Colore e forma:SolidPeso molecolare:556.58Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Formula:C26H21F3N4O4Purezza:99.67% - 99.75%Colore e forma:SolidPeso molecolare:510.46BMS817378
CAS:<p>BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).</p>Formula:C24H18ClF2N4O7PPurezza:>99.99%Colore e forma:SolidPeso molecolare:578.85Crizotinib
CAS:<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Formula:C21H22Cl2FN5OPurezza:99% - 99.87%Colore e forma:SolidPeso molecolare:450.34Foretinib
CAS:<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Formula:C34H34F2N4O6Purezza:98.07% - 99.68%Colore e forma:SolidPeso molecolare:632.65X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Formula:C25H25Cl2FN6O3Purezza:97.87%Colore e forma:SolidPeso molecolare:547.41Capmatinib 2HCl.H2O
CAS:<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H21Cl2FN6O2Purezza:99.77%Colore e forma:SolidPeso molecolare:503.36Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Formula:C32H33ClFN5O11Purezza:98.11% - 99.87%Colore e forma:SolidPeso molecolare:718.08AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Formula:C22H17N5O2Purezza:98.56%Colore e forma:SolidPeso molecolare:383.4
